Like women, old female rhesus macaques undergo menopause and show many of the same age-associated changes, including perturbed activity/rest cycles and altered circulating levels of many hormones. Previous studies showed that administration of an estrogen agonist increased activity in female monkeys, that hormone therapy (HT) increased activity in postmenopausal women and that obesity decreased activity in women. The present study sought to determine if postmenopausal activity and circulating hormone levels also respond to HT when monkeys are fed a high-fat, highsugar Western style diet (WSD). Old female rhesus macaques were ovo-hysterectomized (OvH) to induce surgical menopause and fed a WSD for 2 years. Half of the animals received estradiol-17β (E), beginning immediately after OvH, while the other half received placebo. Animals in both groups showed an increase in body weight and a decrease in overall activity levels. These changes were associated with a rise in both daytime and nocturnal serum leptin concentrations, but there was no change in serum concentrations of either cortisol or dehydroepiandrosterone sulfate (DHEAS). These data suggest that 2 years of HT has little or no effect on locomotor activity or circadian hormone patterns in menopausal macaques fed an obesogenic diet.
Introduction
Like elderly women, old female rhesus macaques show a marked decline in circulating E concentrations (1) , and several monkey studies have demonstrated the therapeutic potential of E or a selective estrogen receptor modulator (SERM) supplementation on age-associated cognitive decline and activity (2, 3, 4, 5, 6) . However, the monkeys in the above studies were fed a standard primate chow that was low in fat and sugar, but high in micronutrients. Therefore, it is unclear if age-associated perturbations of activity-rest cycles and alterations in circadian hormone patterns are exacerbated after menopause by maintenance on a typical high-fat, high-sugar WSD and, more importantly, if these changes can be overcome by E supplementation. In the present study, we examined these issues using a nonhuman primate model of surgical menopause, in which old rhesus macaques were OvH and fed a WSD for 2 years. Although expected changes in body weight, level of activity and circulating hormone levels were observed, there was no obvious difference between the E-treated animals and placebo controls. 
Experimental design
Approximately 6 weeks after the start of the WSD, all of the animals were OvH. Half (n = 7) were immediately started on HT in the form of E-containing silastic capsules, which achieved serum E concentrations of 82.1 ± 0.9 pg/ mL; the other half (n = 7) received empty capsules (placebo), which achieved serum E concentrations of 6.6 ± 0.2 pg/mL on average over 2 years. Serum E was measured every 2 months and the capsule replaced or its size adjusted as deemed appropriate. Animals that showed abnormally low activity prior to WSD were excluded in order to determine whether there was an effect of E on activity. Blood samples were collected from each animal under ketamine HCl sedation (10 mg/kg body weight, intramuscular), at Month −1 and again at Month 24; the serum was stored frozen at −20°C and subsequently assayed for leptin, cortisol and DHEAS. Note, because many hormones show a circadian pattern of secretion (7) two blood samples were collected at each time point, one at ~08:00 h and one at ~20:00 h.
Monitoring of 24-h activity
As previously described (8) , each animal was fitted with an Actiwatch activity monitor (Philips-Respironics), worn inside a protective case that was attached to a lightweight loose-fitting aluminum collar (Primate Products, Inc., Immokalee, FL, USA). At the start of the study, 24-h activity recordings were made for 10 consecutive days and a characteristic baseline pattern was established for each animal; activity was again monitored at the end of the study. The actograms were subsequently analyzed using Actiware-Sleep (version 3.4) software (Cambridge Neurotechnology Ltd, Cambridge, UK). The mean total daily activity (defined as the average 24-h activity) was calculated for each animal, as was the mean daytime activity (defined as activity during the period between 07:00 h and 19:00 h) and mean nighttime activity (activity between 19:00 h and 07:00 h).
Hormone measurements
Plasma leptin concentrations were determined by RIA (Linco Research) with a detection limit of 0.25 ng/mL. The intra-assay coefficients of variation were 5.6% at 3.5 ng/mL and 6.0% at 21.1 ng/mL. The corresponding inter-assay coefficients of variation were 7.9 and 7.0% respectively. E was assayed using a Roche Diagnostics Cobas e411 automatic clinical platform assay instrument. The intra-assay and inter-assay coefficients of variation were all less than 10% and the assay detection limit was 5 pg/ mL. Cortisol was assayed by electro-chemiluminescence using the Elecsys 2010 Platform (Roche Diagnostics). DHEAS was assayed using RIA with a highly specific antibody for DHEAS-17-(O-carboxymethyl)oxime-BSA (Endocrine Services, Tarzana, CA, USA) and [3H]DHEAS (SA, 22 Ci/mmol). For the cortisol and DHEAS assays, the intra-assay and inter-assay coefficients of variation were less than 10% and the assay detection limits were 3 ng/mL.
Statistical analysis
RM ANOVAs followed by Fisher's LSD procedure were used to assess the effects of time and to compare mean values from the same animals at Month −1 and Month 24. P < 0.05 was considered to be significant.
Results
Differences in body weight, activity patterns and serum hormone concentrations, between Month −1 and Month 24 are depicted in Table 1 ; the table also depicts pooled data from the two time points. Body weight showed a significant (P < 0.001) increase after 2 years of maintenance on a WSD. In addition, overall activity as well as daytime activity (P < 0.01), but not nocturnal activity, showed a significant decrease in all animals (Fig. 1 ). There was a 17% decrease in combined groups, a 20% decrease in the OvH + placebo group and a 15% decrease in the OvH + E group in overall activity. For daytime activity only, there was an 18% decrease in combined groups, a 20% decrease in the OvH + placebo group and a 16% decrease in the OvH + E group. There appeared to be little difference in the reduction of activity between the two groups. The associated circadian hormones showed expected AM/PM differences, with serum leptin levels being highest at night, and serum cortisol and DHEAS levels being highest during the day. However, there was no significant change between Month −1 and Month 24 for the two adrenal steroids (cortisol and DHEAS), whereas leptin showed a significant (P < 0.001) increase during both the day and night. Overall, there were no significant differences in activity or hormone responses shown by the placebo-and E-treated monkeys fed WSD for 2 years.
Discussion
Two-thirds of the US population is considered to be overweight or obese, and this may adversely affect the responses of postmenopausal women to HT. In female rhesus macaques fed standard primate chow, SERM treatment caused weight loss with an increase in physical Values represent means ± s.e.m. of 7 animals. **P < 0.01, ***P < 0.001, (RM ANOVA, effect of time); # P < 0.05, ## P < 0.01 (RM ANOVA, followed by Fisher's LSD test). E, estradiol-17β; OvH, ovo-hysterectomized.
Figure 1
Representative actograms from an old female rhesus macaque maintained on a WSD. Activity recordings were made at Month −1 (i.e., ~1 month before exposure to a WSD and 2.5 months before OvH), and again at Month 24 (i.e., 25 months later). In the upper panels, the height of the vertical lines is indicative of the intensity of physical activity at any particular time of day; the mean 24-h activity profiles across the 10 consecutive days are depicted in the lower panels. The horizontal black and white bars correspond to the times of night and day, respectively.
